FDAnews Drug Daily Bulletin
Pharmaceuticals / Submissions and Approvals

FDA Approves Pfizer’s Lorbrena

Nov. 13, 2018

The FDA approved Pfizer’s Lorbrena (lorlatibin) for treating patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease.

The inhibitor is also cleared for treating patients whose diseases have progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

The agency’s green light for Lorbrena marks Pfizer’s third approval for an oncology treatment — including two lung cancer treatments — within two months.

View today's stories